课题基金 / 基金详情

Rett Syndrome (RTT)

Rett Syndrome (RTT)
雷特综合症 (RTT)
批准号:
8381940
负责人:
Alan Kenneth Percy
金额:
$17.32万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2014-07-31
关键词:
AffectAgeAlabamaAmericanAngelman SyndromeAnimal ModelAnxietyAustraliaBehaviorBostonCause of DeathCessation of lifeCharacteristicsChicagoClinicClinicalClinical ResearchClinical TrialsCollaborationsCommunicationDataDatabasesDecelerationDevelopmentDevelopmental DisabilitiesDiseaseEnrollmentFamilyFamily memberFemaleFosteringFoundationsFranceFunctional disorderFundingFutureGait abnormalityGene TargetingGenesGeneticGenotypeGeographic DistributionGoalsGrowthHandHeadHealth PersonnelHyperventilationIndividualInstitutional Review BoardsInstructionIntellectual functioning disabilityInternationalInterventionIsraelJapanLaboratory StudyLifeLongevityLongitudinal StudiesManualsMedicalMedicineMental Retardation and Developmental Disabilities Research CentersMethyl-CpG-Binding Protein 2Molecular GeneticsMonitorMotorMutationNational Center for Research ResourcesNatural HistoryNeurobiologyNew BrunswickNutritionalOsteopeniaParentsParticipantPatientsPatternPediatric HospitalsPhenotypePhysiciansPilot ProjectsPopulationPopulation DensityPrader-Willi SyndromeProgress ReportsRare DiseasesRegistriesResearchResearch PersonnelResourcesRett SyndromeSWI1Sample SizeSamplingSeizuresSiteSleepSleep disturbancesSpainSpecificitySystemTimeTrainingTraining ProgramsTraining and EducationTravelU-Series Cooperative AgreementsUniversitiesUrsidae FamilyVariantbaseclinical Diagnosisclinical phenotypecohortcollegeeffective interventioneffective therapyexpectationfollow-upgastrointestinalgeographic populationimprovedinterestinternational centerknockout animalmalemeetingsmotility disordernervous system disordernovel diagnosticsnutritionoperationoptimismpatient registryresearch clinical testingscoliosisskillssurveillance studytreatment trialweb site

项目摘要

项目成果

Alan Kenneth Percy的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a competitive renewal application from an inter-institutional group of investigators with long-standing interest in Angelman syndrome (AS), Rett syndrome (RTT), and Prader-Willi syndrome (PWS) to continue a Rare Diseases Clinical Research Center (RDCRC) within the Rare Diseases Clinical Research Network (RDCRN). The Center will focus on these three disorders based on the expectation that the near-term potential for meaningful therapy is strong. The specific aims for RTT will be 1) to establish phenotype/genotype correlations over a broad spectrum of Rett phenotypes, 2) to perform longitudinal studies on an extensive population of individuals with Rett, and 3) to extend the survival study on a broad spectrum of Rett individuals. Recent results from studies in animal models provide a basis for clinical trials in the next 5 years. In addition, evidence emerging from the proposed pilot study on sleep dysfunction in the three disorders should provide the basis for a clinical trial on sleep in RTT. The RTT component sites include UAB, Children's Hospital Boston, Greenwood Genetic Center, and Baylor College of Medicine. GCRCs will be utlized in Birmingham, Boston, and Houston. The travel clinics in Oakland, Chicago, New Brunswick, and Miami will continue to provide geographic diversity for study participants. The Center is expected to function synergistically with the Intellectual and Developmental Disability Center-IDDRC (formerly the MRRC) at UAB, Children's Hospital Boston, and Baylor. An extensive training program is proposed for stimulating the entry of new investigators into clinical research on rare diseases (funded by IRSF and PWSA). The RTT sites will have active affiliation with the International Rett Syndrome Foundation (IRSF). A website for this RDCRC is available at www.circ.uab.edu. This site will be amplified to include a wide range of information on all three disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Angelman Syndrome (AS)
Training and Career Development Component
RDCRC Administrative Unit
Angelman Syndrome (AS)
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: